Thus, by regulating the miR-3619-5p/CTNNB1 axis, circZFR activated the Wnt/β-catenin signaling pathway, allowing circZFR silencing as a novel therapeutic target for HCC (106). The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.